LONDON, June 18 /PRNewswire/ --
- Speciality Urology Company Gains Exclusive UK Distribution Rights
Speciality European Pharma Limited (SEP), the UK based, urology focused, specialty pharmaceutical company, is pleased to announce that it will obtain the exclusive distribution rights to Regurin(R) (trospium chloride) for the UK and Ireland, as of the 1st July 2009. Regurin, owned by Rottapharm-Madaus, is currently marketed under different brand names in European countries including Germany, Italy, Austria, Spain and Switzerland.
Regurin is licensed for use in men and women to treat the symptoms of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder (OAB). Urinary incontinence is an embarrassing problem estimated to affect over a third of women over 40. Regurin is an anti-muscarinic, which reduces the contractions of the detrusor muscle in the bladder and increases bladder capacity. It is well tolerated with a low incidence of the common anti-muscarinic side effect, dry mouth., Regurin also does not cross the blood-eye or blood-brain barrier,, reducing the incidence of confusion in people taking this treatment.,,,
"Trospium chloride is central to managing certain types of urinary
incontinence and is one of the recommended options by the National Institute
for Health and Clinical Excellence (NICE) for use in women with mixed urinary
incontinence of OAB after generic oxybutynin," said Professor Linda Cardozo,
Commenting on the deal, Geoff McMillan, Chief Executive Officer of SEP,
said: "This agreement provides us with a well established and clinically
superior product in the field of urology, an area that remains the focus of
our company. This deal demonstrates our
|SOURCE Speciality European Pharma|
Copyright©2009 PR Newswire.
All rights reserved